Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
BioSpace11h
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Business Wire12h
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission ...
GlobalData on MSN11h
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Medscape3d
HPV Vaccine ‘Very Promising’ for Nixing Precancerous Lesions
A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...
Bristol Myers announces results from Phase 2 TRANSCEND FL trial
Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...